FOR IMMEDIATE RELEASE

Washington, D.C. | March 26, 2025

HyperVigilant Inc., an AI-driven health equity company, is proud to introduce its inaugural Advisory Board, bringing together nationally respected leaders in medicine, technology, and innovation. These experts will guide the company’s mission to revolutionize hypertension detection and management through artificial intelligence, especially among underserved communities.

“These advisors represent the best in their fields,” said Dr. Maya Rockeymoore Cummings, Founder and CEO of HyperVigilant. “Each brings a unique lens to our mission, from pediatric pain care to global health equity. Their insight will help shape our platform’s development and our national strategy.”

Meet the Advisory Board

Dr. Meredith Brooks

Children’s Pain Specialist, Cook Children’s Hospital  

An expert in holistic pediatric pain management, Dr. Brooks draws from her leadership in children’s health and advanced training at Johns Hopkins University.

Dr. Richard Allen Williams

Founder, Association of Black Cardiologists  

A nationally recognized cardiologist and champion of equitable healthcare, Dr. Williams is a pioneer in addressing cardiovascular disparities and was honored with Harvard Medical School’s Lifetime Achievement Award.

Dr. Cori Lathan 

Technologist & Founder, AnthroTronix  

Dr. Lathan is an AI and robotics innovator with a Ph.D. from MIT. She is a trailblazer in human-centered technology design and neuro-engineering.

Dr. Nadine Jackson McCleary  

Clinician, Brigham and Women’s Hospital  

A passionate advocate for women’s and minority health, Dr. McCleary blends clinical expertise with research and policy innovation to build inclusive, equity-focused health systems.

Arthur Summerville  

CEO, Medical Innovations LLC  

With decades of global experience in healthcare and pharmaceutical distribution, Mr. Summerville lends strategic insight into HyperVigilant’s market development and operations.

About HyperVigilant

HyperVigilant is developing an AI-powered health platform that predicts, diagnoses and manages hypertension with precision and equity. The company’s approach integrates clinical, behavioral, and social health data to create culturally responsive care solutions. With a focus on transforming chronic disease outcomes in vulnerable populations, HyperVigilant is partnering with public systems, hospitals, and health plans to develop and launch its MVP.

Learn more at www.HyperVigilant.com.